


Perspectives on Current Quality and Bioequivalence Challenges for Complex Products

Andre O'Reilly Beringhs, Ph.D.
Staff Fellow – ORS/OGD/CDER/FDA

Renishkumar Delvadia, Ph.D.
Senior Staff Fellow – OPQ/CDER/FDA

DISCLAIMER: The views and opinions presented here represent those of the speakers and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.

GDUFA-driven Breakthroughs Pave the Way to ANDA Approvals



Budesonide; Formoterol Fumarate Metered Dose Inhaler

- Reduce the need of clinical endpoint studies

Naltrexone for Extended-Release Injectable Suspension Alternative methods to support drug product sameness



Cyclosporine Ophthalmic Emulsion

Q1/Q2/Q3 microstructure fingerprinting in lieu of in-vivo trials

The takeaway is simple: GDUFA regulatory-science investments pay tangible dividends in faster, lower-cost approvals, especially for complex generic products


Topical Dermatological and Transdermal Products

Topic	Quality/Bioequivalence Challenges	Exploratory Ideas
Topical Semisolids	• IVPT implementation • Q3 assessment for Q3-similar products	• Q3 'safe space' and performance relationship
Integrated Modeling	• Model validation and implementation • No model-only BE approaches in PSGs	• Totality-of-evidence via Q3 + modeling
Transdermal and Topical Delivery Systems	• Lack of biorelevant in vitro adhesion tests • Skin irritation and sensitization	• Skin-mimetic adhesion tests

Inhalation and Nasal Products

Topic	Quality/Bioequivalence Challenges	Exploratory Ideas
Dry Powder Inhalers (DPIs)	• High inter-batch variability • Particle-aerosol performance link	• High-res morphology mapping • Variability deconvolution studies
Metered Dose Inhaler (MDIs) & Next Generation Propellants	• Spray/APSD variability with new propellants; • BE framework or design space	• Map formulation-device interactions • PBPK and in vitro - in silico models
Nasal and Nose-to-Brain Products	• No validated regional deposition models • Unclear CNS delivery target site	• Develop 3D nasal models with deposition readouts • Pilot CNS surrogate endpoints in preclinical models

Complex Injectables



Topic	Quality/BE Challenges	Exploratory Ideas
In-situ Forming Depots	- Validated in vitro models for depot formation - High variability from injection factors	- Injectability rigs and imaging - Physiologically-relevant dissolution models
Nanoparticle-based Injectables	Impact of albumin-bound stabilizers on nanoparticle BE and quality	- Profile stabilizer levels - Risk-assessment framework for stabilizer differences
Q1/Q2 Flexibilities	Impact of minor formulation differences on BE	- Q3/Q4 fingerprinting + PBPK modeling - Science-based “safe-harbor” for formulation variations


Ophthalmic and Otic Products

Topic	Quality/Bioequivalence Challenges	Exploratory Ideas
Intra-ocular Implants	- Predict long-term ocular PK - Structure-release relationships	- Modular toolkit (micro-CT, Raman, USP 4) - PBPK modeling
Posterior-segment Depots	Q1/Q2/Q3 impact on vitreous depot behavior	- Use vitreous-mimic chamber - IVIVC models
Permissible Excipient Differences	- Impact of Q1/Q2 differences - Equivalent substitutes	AI-based Q3 fingerprinting with in/ex vivo data
Otic Suspensions & Gels	In vitro model reflecting middle ear permeability	Tympanic organ-chip with real-time permeation for PK prediction

Peptide and Oligonucleotide Products

Topic	Quality/Bioequivalence Challenges	Exploratory Ideas
Oral and Nasal Peptides	- In vitro models for enhancer-driven absorption - Simulation of mucosal dynamics	Epithelial perfusion models with real-time protease/enhancer tracking
Depot-forming Peptides	- Tools to model long-acting depot PK - Depot structure-PK linkage	SANS/SAXS + depot-shrinkage imaging with subQ release modeling
Oligonucleotides	- Impurity characterization - Potential off-target and/or immunogenicity risks	Orthogonal impurity profiling platforms for low-level process- and sequence-related impurities

AI Tools Applied to Complex Generics



Call to Action!



More Info & Opportunities at <https://www.fda.gov/drugs/generic-drugs/science-research>

